Pharmacokinetic Studies and Evaluation of Nanoparticulate Drug Delivery System in the Treatment of Cancer

Cancer is a leading cause of mortality globally. The rising incidence of cancer worldwide has presented a significant challenge to healthcare practitioners. The primary forms of cancer are associated with elevated mortality rates. Cancer therapies encompass surgery, chemotherapy, radiation, and immunotherapy; chemotherapy remains the primary modality. For many decades, the predominant method of chemotherapy has been intravenous drug delivery, which presents disadvantages such as safety concerns, discomfort, and suboptimal patient compliance. Conversely, oral medication has numerous advantages, including ease of administration, enhanced safety, and greater patient acceptance. In this study, we have developed a unique lipid-based drug delivery system for methotrexate and paclitaxel to enhance their bioavailability and efficacy. Methotrexate and Paclitaxel had the highest accumulation in the spleen, liver, and kidney, which may facilitate enhanced drug delivery in small cell carcinoma, hence improving efficacy. Methotrexate and Paclitaxel had the highest accumulation in the spleen, liver, and kidneys, which may facilitate improved drug delivery in small cell cancer.